新型降脂药物的应用研究进展
Lipid-lowering therapy in the post-statin era
以LDL-C升高为主的血脂异常与动脉粥样硬化性心血管疾病(ASCVD)密切相关,他汀类药物是降低LDL-C最有效的药物,在预防和治疗ASCVD方面起着非常重要的作用.但相当一部分患者接受他汀治疗后LDL-C不能达标或者不能耐受他汀的不良反应,心血管残余风险仍然很高.新型降脂药物如依折麦布、前蛋白转化酶枯草溶菌素9型(PCSK9)抑制剂、胆固醇酯转运蛋白(CETP)抑制剂的临床应用使调脂治疗进入了“后他汀时代”,现对此研究进展进行综述.
更多Atherosclerotic cardiovascular disease is one of the leading causes of death and disability worldwide.Dyslipidemia mainly with elevated LDL-C is closely related to atherosclerotic cardiovascular disease.Statins are the most effective drugs for lowering LDL-C and play an important role in the prevention and treatment of atherosclerotic cardiovascular disease.However,a considerable number of patients receiving statin therapy can not tolerate its adverse reactions or their low-density lipoprotein can not meet the standard,and the cardiovascular risk remains high.The clinical application of new lipid-lowering drugs such as ezetimibe,PCSK9 inhibitors and cholesterol ester transfer protein(CETP) inhibitors has marked the post-statin era of lipid-lowering therapy.
More- 浏览:195
- 被引:8
- 下载:341
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文